Furthermore, interventional treatments with canakinumab and IL-1Ra agonist (anakinra) demonstrated a key pathological role of IL-1β in the induction of inflammation-related diseases.356 These findings, therefore, provided evidence that inhibition of IL-1β could ameliorate the clinical outcome of cardiovascular disease. This evidence concerns the gene IL1B and cardiovascular disorder.